immune thrombocytopenic purpura
Haematology · 2010–2014
4decisions
2medicines
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| eltrombopag Treatment of severe chronic immune (idiopathic) thrombocytopenic purpura (ITP) in adult patients. The submission sought to amend the continuation restriction… | Nov 2014 | Not recommended | unclear |
| eltrombopag Initial treatment, as the sole PBS-subsidised thrombopoietin receptor agonist (TRA), of severe thrombocytopenia in an adult patient with severe chronic immune… | Mar 2011 | Recommended with restriction | no section in document |
| romiplostim Initial and continuing treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who meet specific… | Mar 2010 | Recommended with restriction | no section in document |
| romiplostim Initial and continuing treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who are either… | Mar 2010 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.